Renovacor Inc

Renovacor, Inc. is a preclinical-stage gene therapy company. The Company is engaged in developing a pipeline of adeno-associated virus (AAV)-based gene therapies for Bcl2-associated athanogene 3 (BAG3) gene mutation-associated diseases in areas of unmet medical need. The Company's therapeutic focuses on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

BAG3-associated dilated cardiomyopathy (DCM) is a rare, genetically driven form of heart failure, which has a high unmet medical need due to no commercially available targeted treatments.

BAG3 protein is expressed predominantly in the heart, where it has multiple functions within the cell due to the presence of multiple protein binding sites. BAG3 protein has roles in maintenance of the sarcomeres, normalization of protein quality control, inhibition of programmed cell death, and responsiveness to adrenergic signals. Because BAG3 plays a role in multiple critical myocardial cell functions, we believe gene replacement therapy offers unique potential to directly restore proper cellular function.